The effects of the adenosine A(2a) receptor antagonist, Quinazoline, on the monoamine transmitters NA, DA, 5-HT and 5-HIAA was studied using fluorecent method, and the influence of MPTP(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and Quinazoline (CP66713) on the GABA positive reaction cells in globus pallidus was determined by immunohistochemistry technique in MPTP treated Parkinsonian mice. The results showed that MPTP decreased the content of DA, 5-HIAA and increased 5-HT, GABA obviously(pp<0.01). Quinazoline functioned opposite the action of MPTP, increasing the content of DA, 5-HIAA and decreasing the 5-HT. Quinazoline also reduced the GABA-positive reaction cells in globus pallidus of control mice and maintained the level of GABA-positive reaction cells of globus pallidus in MPTP treated mice, making it similar with the level of control.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update.
Expert Opin Pharmacother
January 2025
Department of Obstetrics and Gynecology, University of Florence, Careggi University Hospital, Florence, Italy.
Introduction: Dysmenorrhea is a painful symptom associated with uterine contractions and menstrual bleeding and is treated by administering analgesic drugs. Since progesterone receptors (PRs) have a major role in regulating uterine tissues (myometrium and endometrium) oral contraceptives are used off-label for treating primary or secondary dysmenorrhea. The development of selective progesterone receptor modulators (SPRMs) a class of synthetic steroids with agonistic, antagonistic, or mixed effects in targeting PRs in different tissues stimulated their possible clinical use for treating secondary dysmenorrhea related to uterine diseases (endometriosis, adenomyosis, uterine fibroids).
View Article and Find Full Text PDFKetamine Infusion for Complex Regional Pain Syndrome Treatment: A Narrative Review.
Curr Pain Headache Rep
January 2025
Department of Anesthesiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, 71103, USA.
Purpose Of Review: Complex Regional Pain Syndrome (CRPS) is a neuropathic pain disorder characterized by pain disproportionate to the inciting event that is constant for an extended duration. Numerous treatment options for this condition have been explored with unsatisfactory results in many cases. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist typically used as an anesthetic and analgesic, presents a promising potential treatment for CRPS in patients who fail to respond to traditional therapies.
View Article and Find Full Text PDFThe additive effect between citalopram and muscimol upon induction of antinociceptive effect in male mice.
IBRO Neurosci Rep
December 2024
Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Previous investigations have revealed the role of GABAergic and serotonergic systems in the modulation of pain behavior. This research aimed to examine the effects of intracerebroventricular (i.c.
View Article and Find Full Text PDFRemimazolam Suppresses Oxidative Stress and Apoptosis in Cerebral Ischemia/Reperfusion Injury by Regulating AKT/GSK-3β/NRF2 Pathway.
Drug Des Devel Ther
January 2025
Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Introduction: The mechanism of remimazolam, a benzodiazepine that activates γ-aminobutyric acid a (GABAa) receptors, in cerebral ischemia/reperfusion (I/R) injury is not well understood. Therefore, we explored whether remimazolam activates protein kinase B (AKT)/glycogen synthase kinase-3β (GSK-3β)/nuclear factor erythroid 2-related factor 2 (NRF2) to attenuate brain I/R injury in transcerebral I/R-injured rats and transoxygenic glucose deprivation/reperfusion (OGD/R)-injured SY5Y cells.
Material And Methods: Remimazolam was added at the beginning of cell and rat reperfusion, and the PI3K/AKT inhibitor LY294002 was added to inhibit the AKT/GSK-3β/NRF2 pathway 24 h before cellular OGD/R treatment and 30 min before rat brain I/R treatment.
Chrysin: A Potential Antiandrogen Ligand to Mutated Androgen Receptors in Prostate Cancer.
Curr Mol Pharmacol
January 2025
Medical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco A.C., 44270, Guadalajara, Jalisco, Mexico.
Background: Androgen receptor mutations, particularly T877A and W741L, promote prostate cancer (PCa). The main therapies against PCa use androgen receptor (AR) antagonists, including Bicalutamide; but these drugs lose their effectiveness over time. Chrysin is a flavonoid with several biological activities, including antitumoral properties; however, its potential as an antiandrogen must be explored.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!